mTOR、VEGFR-2、PDGFR-β和CD117在软组织肉瘤中的表达与预后分析

发布时间：2018-04-18 15:42

本文选题：软组织肉瘤 + 免疫组化　；参考：《新疆医科大学》2015年硕士论文

【摘要】：目的：探讨雷帕霉素靶蛋白(mammalian target of rapamycinm, mTOR)、血管内皮生长因子受体2(vascular epidemal growth factor receptor-2, VEGFR-2)、血小板衍生生长因子受体β(platelet-derived growth factor receptor beta, PDGFR-β)和CD117在软组织肉瘤中表达的临床意义及对预后的影响。方法：收集新疆医科大学附属肿瘤医院骨与软组织科2006年1月至2010年12月收治的94例软组织肉瘤患者病理和临床资料,应用组织芯片技术及PV-9000免疫组化方法检测94例软组织肉瘤中mTOR、VEGFR-2、PDGFR-β和CD117的表达,分析其与临床病理特征和预后的关系。结果：1.94例软组织肉瘤患者的中位PFS和OS分别为17个月(95%CI:10.639-23.361个月)和68.0个月(95%CI:61.806-74.194个月),3年生存率为71.0%,5年生存率为65.2%。2.mTOR、VEGFR-2、PDGFR-β和CD117在软组织肉瘤中高表达率分别为：67.0%(63/94)、68.7%(64/94)、38.3%(36/94)、7.4%(7/94)。3.mTOR的表达与肿瘤病理类型,大小及临床分期有关(P0.05),与性别、年龄、部位、深浅、组织学分级无关(P0.05)；VEGFR-2的表达与肿瘤病理类型、年龄有关(P0.05),与性别、肿瘤部位、大小、深浅、组织学分级、临床分期无关(P0.05)；PDGFR-P的表达与肿瘤的深浅及组织学分级有关(P0.05)；CD117的表达与临床病理特征间未见统计学意义的相关性。4.软组织肉瘤的手术切缘、mTOR的表达与PFS/OS相关(P0.05)。结论：1.mTOR、VEGFR-2在软组织肉瘤中高表达；2.mTOR和PDGFR-β高表达和阳性切缘是软组织肉瘤预后不良指标；3.mTOR、VEGFR-2、 PDGFR-β在软组织肉瘤中表达情况为软组织肉瘤的靶向治疗提供理论参考。免疫组化检测CD117在软组织肉瘤中的表达局限。
[Abstract]:Objective : To investigate the clinical significance and prognostic significance of rapamycin target protein ( mtor ) , vascular endothelial growth factor receptor - 2 ( VEGFR - 2 ) , platelet - derived growth factor receptor - 2 ( VEGFR - 2 ) , platelet - derived growth factor receptor beta ( PDGFR - 尾 ) and CD117 in soft tissue sarcoma .
The expression of VEGFR - 2 was related to the pathological type and age of tumor ( P0.05 ) . The expression of VEGFR - 2 was not related to sex , tumor site , size , depth , histological grade and clinical stage ( P0.05 ) .
The expression of PDGFR - P is related to the superficial and histological grade of tumor ( P0.05 ) .
There was no significant correlation between the expression of CD117 and clinicopathological features . 4 . The expression of mtor was correlated with PFS / OS in soft tissue sarcoma ( P0.05 ) . Conclusion : 1 . High expression of mtor and VEGFR - 2 in soft tissue sarcoma .
2 . High expression and positive margins of mtor and PDGFR - 尾 are poor prognostic indicators of soft tissue sarcoma ;
3 . The expression of mtor , VEGFR - 2 and PDGFR - 尾 in soft tissue sarcoma provides a theoretical reference for the targeted therapy of soft tissue sarcoma . The expression of CD117 in soft tissue sarcoma is limited by immunohistochemistry .

【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R738.6

【相似文献】